Novel therapeutic targets in non-small cell lung cancer

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 394-401

  Alamgeer, Muhammad ^a,b   Ganju, Vinod ^a,b   Watkins, D Neil ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; AP 26113; AV 412; BMS 690514; CARBOPLATIN; CH 5424802; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; LAPATINIB; LDK 378; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PEMETREXED; PHOSPHOTRANSFERASE INHIBITOR; RIDAFOROLIMUS; SCATTER FACTOR RECEPTOR; SELUMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 647;

ACNE; ANTINEOPLASTIC ACTIVITY; C MET GENE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EDEMA; EGFR GENE; EML4 ALK GENE; FUSION GENE; GENE MUTATION; HUMAN; KIDNEY CYST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NAUSEA; ONCOGENE K RAS; PHARMACOLOGICAL BLOCKING; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RET GENE; REVIEW; VISUAL DISORDER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84879113773     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.03.010     Document Type: Review

References (62)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. W.D. Travis, T.V. Colby, and B. Corrin Histological Typing of Lung and Pleural Tumours edn 3 1999 Springer-Verlag Berlin
3. L. West, S.J. Vidwans, N.P. Campbell, J. Shrager, G.R. Simon, R. Bueno, P.A. Dennis, G.A. Otterson, and R. Salgia A novel classification of lung cancer into molecular subtypes PLoS ONE 7 2012 e31906
4. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, and F.G. Haluska Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
5. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, and T.J. Boggon EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
6. T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824
7. A. Sakurada, F.A. Shepherd, and M.S. Tsao Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations Clin Lung Cancer 7 Suppl 4 2006 S138 S144
8. H. Greulich, T.H. Chen, W. Feng, P.A. Janne, J.V. Alvarez, M. Zappaterra, S.E. Bulmer, D.A. Frank, W.C. Hahn, and W.R. Sellers Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med 2 2005 e313
9. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, and B. Halmos EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
10. Y. Miyamae, K. Shimizu, J. Hirato, T. Araki, K. Tanaka, H. Ogawa, S. Kakegawa, M. Sugano, T. Nakano, and Y. Mitani Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma Oncol Rep 25 2011 921 928
11. N. Rekhtman, P.K. Paik, M.E. Arcila, L.J. Tafe, G.R. Oxnard, A.L. Moreira, W.D. Travis, M.F. Zakowski, M.G. Kris, and M. Ladanyi Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations Clin Cancer Res 18 2012 1167 1176
12. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R.B. Natale, J.H. Schiller, J. Von Pawel, and A. Pluzanska Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
13. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, and J.A. Reeves Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
14. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, and Y. Ichinose Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
15. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, and I. Kinoshita Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
16. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, and T. Hirashima Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
17. A. Inoue, K. Kobayashi, K. Usui, M. Maemondo, S. Okinaga, I. Mikami, M. Ando, K. Yamazaki, Y. Saijo, and A. Gemma First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
18. C. Zhou, Y.L. Wu, G. Chen, J. Feng, X.Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, and S. Ren Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
19. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, and J.M. Sanchez Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
20. U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, F. De Rosa, J. Milanowski, H. Karnicka-Mlodkowski, M. Pesek, and P. Serwatowski Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552
21. R.S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B.E. Johnson, A. Sandler, M.G. Kris, H.T. Tran, P. Klein, and X. Li TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
22. J.Y. Douillard, F.A. Shepherd, V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, M.L. Liao, H. Bischoff, M. Reck, and M.V. Sellers Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 2010 744 752
23. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E.H. Tan, K. Pemberton, and V. Archer Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
24. E.S. Kim, V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, Y.L. Wu, L.Y. Li, C.L. Watkins, M.V. Sellers, and E.S. Lowe Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
25. M. Fukuoka, Y.L. Wu, S. Thongprasert, P. Sunpaweravong, S.S. Leong, V. Sriuranpong, T.Y. Chao, K. Nakagawa, D.T. Chu, and N. Saijo Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
26. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, and R. Martins Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
27. F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicenas, A. Szczesna, E. Juhasz, E. Esteban, O. Molinier, W. Brugger, and I. Melezinek Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
28. T. Kosaka, Y. Yatabe, R. Onozato, H. Kuwano, and T. Mitsudomi Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol 4 2009 22 29
29. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
30. M.N. Balak, Y. Gong, G.J. Riely, R. Somwar, A.R. Li, M.F. Zakowski, A. Chiang, G. Yang, O. Ouerfelli, and M.G. Kris Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12 2006 6494 6501
31. S. Thomson, E. Buck, F. Petti, G. Griffin, E. Brown, N. Ramnarine, K.K. Iwata, N. Gibson, and J.D. Haley Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 2005 9455 9462
32. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, P. Fidias, K. Bergethon, A.T. Shaw, S. Gettinger, and A.K. Cosper Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 2011 75ra26
33. C.P. Belani The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors Cancer Invest 28 2010 413 423
34. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, and H. Hatanaka Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
35. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, S.R. Digumarthy, D.B. Costa, R.S. Heist, B. Solomon, H. Stubbs, S. Admane, and U. McDermott Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
36. E.S. Yi, J.M. Boland, J.J. Maleszewski, A.C. Roden, A.M. Oliveira, M.C. Aubry, M.R. Erickson-Johnson, B.L. Caron, Y. Li, and H. Tang Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 2011 459 465
37. J.H. Paik, G. Choe, H. Kim, J.Y. Choe, H.J. Lee, C.T. Lee, J.S. Lee, S. Jheon, and J.H. Chung Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization J Thorac Oncol 6 2011 466 472
38. M. Alamgeer, T. Rogers, S. Fox, and B. Solomon Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements Clin Invest 2 2012 895 907
39. J.G. Christensen, H.Y. Zou, M.E. Arango, Q. Li, J.H. Lee, S.R. McDonnell, S. Yamazaki, G.R. Alton, B. Mroczkowski, and G. Los Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol Cancer Ther 6 2007 3314 3322
40. H.Y. Zou, Q. Li, J.H. Lee, M.E. Arango, S.R. McDonnell, S. Yamazaki, T.B. Koudriakova, G. Alton, J.J. Cui, and P.P. Kung An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res 67 2007 4408 4417
41. H. Yasuda, L.L. de Figueiredo-Pontes, S. Kobayashi, and D.B. Costa Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer J Thorac Oncol 7 2012 1086 1090
42. E.L. Kwak, Y.J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, R.G. Maki, S.H. Ou, B.J. Dezube, P.A. Janne, and D.B. Costa Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
43. R. Katayama, A.T. Shaw, T.M. Khan, M. Mino-Kenudson, B.J. Solomon, B. Halmos, N.A. Jessop, J.C. Wain, A.T. Yeo, and C. Benes Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Transl Med 4 2012 120ra117
44. S. Forbes, J. Clements, E. Dawson, S. Bamford, T. Webb, A. Dogan, A. Flanagan, J. Teague, R. Wooster, and P.A. Futreal Cosmic 2005 Br J Cancer 94 2006 318 322
45. E. Massarelli, M. Varella-Garcia, X. Tang, A.C. Xavier, N.C. Ozburn, D.D. Liu, B.N. Bekele, R.S. Herbst, and I.I. Wistuba KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2007 2890 2896
46. G.J. Riely, J. Marks, and W. Pao KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc 6 2009 201 205
47. C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, M. Dusart, A. Haller, P. Lothaire, A.P. Meert, and S. Noel The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139
48. K.D. Davies, A.T. Le, M.F. Theodoro, M.C. Skokan, D.L. Aisner, E.M. Berge, L.M. Terracciano, F. Cappuzzo, M. Incarbone, and M. Roncalli Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin Cancer Res 18 2012 4570 4579
49. H.J. Jun, H. Johnson, R.T. Bronson, S. de Feraudy, F. White, and A. Charest The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation Cancer Res 72 2012 3764 3774
50. M. Sattler, M.M. Reddy, R. Hasina, T. Gangadhar, and R. Salgia The role of the c-Met pathway in lung cancer and the potential for targeted therapy Ther Adv Med Oncol 3 2011 171 184
51. R. Wang, H. Hu, Y. Pan, Y. Li, T. Ye, C. Li, X. Luo, L. Wang, H. Li, and Y. Zhang RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer J Clin Oncol 30 2012 4352 4359
52. B.H. Chao, R. Briesewitz, and M.A. Villalona-Calero RET fusion genes in non-small-cell lung cancer J Clin Oncol 30 2012 4439 4441
53. M.J. Mulvihill, A. Cooke, M. Rosenfeld-Franklin, E. Buck, K. Foreman, D. Landfair, M. O'Connor, C. Pirritt, Y. Sun, and Y. Yao Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor Future Med Chem 1 2009 1153 1171
54. F. Morgillo, W.Y. Kim, E.S. Kim, F. Ciardiello, W.K. Hong, and H.Y. Lee Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib Clin Cancer Res 13 2007 2795 2803
55. J. Weiss, M.L. Sos, D. Seidel, M. Peifer, T. Zander, J.M. Heuckmann, R.T. Ullrich, R. Menon, S. Maier, and A. Soltermann Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer Sci Transl Med 2 2010 62ra93
56. P. Paik, A. Hasanovic, and L. Wang Multiplex testing for driver mutations in squamous cell carcinomas of the lung J Clin Oncol 30 2012 (suppl; abstr 7505)
57. H.R. Kim, D.J. Kim, D.R. Kang, J.G. Lee, S.M. Lim, C.Y. Lee, S.Y. Rha, M.K. Bae, Y.J. Lee, and S.H. Kim Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer J Clin Oncol 31 2012 731 737
58. P.R. Gavine, L. Mooney, and E. Kilgour An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3 Proceedings of the American Association of Cancer Research Annual Meeting 2011 (abstr 3568)
59. V. Guagnano, P. Furet, C. Spanka, V. Bordas, M. Le Douget, C. Stamm, J. Brueggen, M.R. Jensen, C. Schnell, and H. Schmid Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase J Med Chem 54 2011 7066 7083
60. G. Zhao, W.Y. Li, D. Chen, J.R. Henry, H.Y. Li, Z. Chen, M. Zia-Ebrahimi, L. Bloem, Y. Zhai, and K. Huss A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models Mol Cancer Ther 10 2011 2200 2210
61. P.S. Hammerman, M.L. Sos, A.H. Ramos, C. Xu, A. Dutt, W. Zhou, L.E. Brace, B.A. Woods, W. Lin, and J. Zhang Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 1 2011 78 89
62. Y. Dobashi, Y. Watanabe, C. Miwa, S. Suzuki, and S. Koyama Mammalian target of rapamycin: a central node of complex signaling cascades Int J Clin Exp Pathol 4 2011 476 495